ID   KMT5A_HUMAN             Reviewed;         393 AA.
AC   Q9NQR1; A8K9D0; Q86W83; Q8TD09;
DT   15-NOV-2002, integrated into UniProtKB/Swiss-Prot.
DT   15-NOV-2002, sequence version 3.
DT   07-APR-2021, entry version 190.
DE   RecName: Full=N-lysine methyltransferase KMT5A {ECO:0000305};
DE            EC=2.1.1.- {ECO:0000305};
DE   AltName: Full=H4-K20-HMTase KMT5A;
DE   AltName: Full=Histone-lysine N-methyltransferase KMT5A;
DE            EC=2.1.1.361 {ECO:0000269|PubMed:12086618, ECO:0000269|PubMed:12121615, ECO:0000269|PubMed:15964846};
DE   AltName: Full=Lysine N-methyltransferase 5A;
DE   AltName: Full=Lysine-specific methylase 5A {ECO:0000312|HGNC:HGNC:29489};
DE   AltName: Full=PR/SET domain-containing protein 07;
DE            Short=PR-Set7;
DE            Short=PR/SET07;
DE   AltName: Full=SET domain-containing protein 8;
GN   Name=KMT5A {ECO:0000312|HGNC:HGNC:29489};
GN   Synonyms=PRSET7, SET07, SET8, SETD8;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), PROTEIN SEQUENCE OF 108-131;
RP   220-231 AND 349-393, FUNCTION, SUBCELLULAR LOCATION, CATALYTIC ACTIVITY,
RP   AND MUTAGENESIS OF ARG-336.
RC   TISSUE=Cervix carcinoma;
RX   PubMed=12086618; DOI=10.1016/s1097-2765(02)00548-8;
RA   Nishioka K., Rice J.C., Sarma K., Erdjument-Bromage H., Werner J., Wang Y.,
RA   Chuikov S., Valenzuela P., Tempst P., Steward R., Lis J.T., Allis C.D.,
RA   Reinberg D.;
RT   "PR-Set7 is a nucleosome-specific methyltransferase that modifies lysine 20
RT   of histone H4 and is associated with silent chromatin.";
RL   Mol. Cell 9:1201-1213(2002).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), PROTEIN SEQUENCE OF 83-103;
RP   109-134; 141-151; 162-172; 221-230; 245-260; 280-297 AND 350-393, FUNCTION,
RP   CATALYTIC ACTIVITY, AND MUTAGENESIS OF HIS-340 AND 385-ILE--HIS-393.
RX   PubMed=12121615; DOI=10.1016/s0960-9822(02)00924-7;
RA   Fang J., Feng Q., Ketel C.S., Wang H., Cao R., Xia L.,
RA   Erdjument-Bromage H., Tempst P., Simon J.A., Zhang Y.;
RT   "Purification and functional characterization of SET8, a nucleosomal
RT   histone H4-lysine 20-specific methyltransferase.";
RL   Curr. Biol. 12:1086-1099(2002).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RA   Tain F., Huang S.;
RT   "A novel PR/SET domain-containing gene, SET07, as a candidate tumor
RT   suppressor.";
RL   Submitted (JUL-2001) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Thymus;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Testis;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   SUBCELLULAR LOCATION, AND DEVELOPMENTAL STAGE.
RX   PubMed=12208845; DOI=10.1101/gad.1014902;
RA   Rice J.C., Nishioka K., Sarma K., Steward R., Reinberg D., Allis C.D.;
RT   "Mitotic-specific methylation of histone H4 Lys 20 follows increased PR-
RT   Set7 expression and its localization to mitotic chromosomes.";
RL   Genes Dev. 16:2225-2230(2002).
RN   [7]
RP   FUNCTION, AND INDUCTION.
RX   PubMed=15200950; DOI=10.1016/j.molcel.2004.06.008;
RA   Julien E., Herr W.;
RT   "A switch in mitotic histone H4 lysine 20 methylation status is linked to M
RT   phase defects upon loss of HCF-1.";
RL   Mol. Cell 14:713-725(2004).
RN   [8]
RP   CATALYTIC ACTIVITY.
RX   PubMed=15964846; DOI=10.1074/jbc.m501691200;
RA   Yin Y., Liu C., Tsai S.N., Zhou B., Ngai S.M., Zhu G.;
RT   "SET8 recognizes the sequence RHRK20VLRDN within the N terminus of histone
RT   H4 and mono-methylates lysine 20.";
RL   J. Biol. Chem. 280:30025-30031(2005).
RN   [9]
RP   FUNCTION.
RX   PubMed=16517599; DOI=10.1074/jbc.m513462200;
RA   Sims J.K., Houston S.I., Magazinnik T., Rice J.C.;
RT   "A trans-tail histone code defined by monomethylated H4 Lys-20 and H3 Lys-9
RT   demarcates distinct regions of silent chromatin.";
RL   J. Biol. Chem. 281:12760-12766(2006).
RN   [10]
RP   FUNCTION, AND MUTAGENESIS OF ASP-379.
RX   PubMed=17707234; DOI=10.1016/j.molcel.2007.07.012;
RA   Shi X., Kachirskaia I., Yamaguchi H., West L.E., Wen H., Wang E.W.,
RA   Dutta S., Appella E., Gozani O.;
RT   "Modulation of p53 function by SET8-mediated methylation at lysine 382.";
RL   Mol. Cell 27:636-646(2007).
RN   [11]
RP   INTERACTION WITH L3MBTL1.
RX   PubMed=18408754; DOI=10.1038/onc.2008.67;
RA   Kalakonda N., Fischle W., Boccuni P., Gurvich N., Hoya-Arias R., Zhao X.,
RA   Miyata Y., Macgrogan D., Zhang J., Sims J.K., Rice J.C., Nimer S.D.;
RT   "Histone H4 lysine 20 monomethylation promotes transcriptional repression
RT   by L3MBTL1.";
RL   Oncogene 27:4293-4304(2008).
RN   [12]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-100, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [13]
RP   MUTAGENESIS OF ASP-379.
RX   PubMed=20870725; DOI=10.1074/jbc.m110.139527;
RA   West L.E., Roy S., Lachmi-Weiner K., Hayashi R., Shi X., Appella E.,
RA   Kutateladze T.G., Gozani O.;
RT   "The MBT repeats of L3MBTL1 link SET8-mediated p53 methylation at lysine
RT   382 to target gene repression.";
RL   J. Biol. Chem. 285:37725-37732(2010).
RN   [14]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-100, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [15]
RP   ACETYLATION AT LYS-172, DEACETYLATION AT LYS-172 BY SIRT2, INTERACTION WITH
RP   SIRT2, SUBCELLULAR LOCATION, MUTAGENESIS OF LYS-172, AND MASS SPECTROMETRY
RP   (ISOFORM 2).
RX   PubMed=23468428; DOI=10.1101/gad.211342.112;
RA   Serrano L., Martinez-Redondo P., Marazuela-Duque A., Vazquez B.N.,
RA   Dooley S.J., Voigt P., Beck D.B., Kane-Goldsmith N., Tong Q., Rabanal R.M.,
RA   Fondevila D., Munoz P., Kruger M., Tischfield J.A., Vaquero A.;
RT   "The tumor suppressor SirT2 regulates cell cycle progression and genome
RT   stability by modulating the mitotic deposition of H4K20 methylation.";
RL   Genes Dev. 27:639-653(2013).
RN   [16]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-181, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [17]
RP   FUNCTION, INDUCTION, UBIQUITINATION, AND MUTAGENESIS OF ARG-336 AND
RP   ASP-379.
RX   PubMed=23478445; DOI=10.1016/j.molcel.2013.02.003;
RA   Abbas T., Mueller A.C., Shibata E., Keaton M., Rossi M., Dutta A.;
RT   "CRL1-FBXO11 promotes Cdt2 ubiquitylation and degradation and regulates Pr-
RT   Set7/Set8-mediated cellular migration.";
RL   Mol. Cell 49:1147-1158(2013).
RN   [18]
RP   X-RAY CRYSTALLOGRAPHY (1.5 ANGSTROMS) OF 233-393 IN COMPLEX WITH HISTONE H4
RP   AND S-ADENOSYLMETHIONINE, AND FUNCTION.
RX   PubMed=15933069; DOI=10.1101/gad.1315905;
RA   Xiao B., Jing C., Kelly G., Walker P.A., Muskett F.W., Frenkiel T.A.,
RA   Martin S.R., Sarma K., Reinberg D., Gamblin S.J., Wilson J.R.;
RT   "Specificity and mechanism of the histone methyltransferase Pr-Set7.";
RL   Genes Dev. 19:1444-1454(2005).
RN   [19]
RP   X-RAY CRYSTALLOGRAPHY (1.45 ANGSTROMS) OF 231-393 IN COMPLEX WITH HISTONE
RP   H4 AND S-ADENOSYLMETHIONINE, FUNCTION, AND MUTAGENESIS OF TYR-286; GLU-300;
RP   CYS-311; TYR-375; ASP-379 AND HIS-388.
RX   PubMed=15933070; DOI=10.1101/gad.1318405;
RA   Couture J.-F., Collazo E., Brunzelle J.S., Trievel R.C.;
RT   "Structural and functional analysis of SET8, a histone H4 'Lys-20'
RT   methyltransferase.";
RL   Genes Dev. 19:1455-1465(2005).
CC   -!- FUNCTION: Protein-lysine N-methyltransferase that monomethylates both
CC       histones and non-histone proteins. Specifically monomethylates 'Lys-20'
CC       of histone H4 (H4K20me1). H4K20me1 is enriched during mitosis and
CC       represents a specific tag for epigenetic transcriptional repression.
CC       Mainly functions in euchromatin regions, thereby playing a central role
CC       in the silencing of euchromatic genes. Required for cell proliferation,
CC       probably by contributing to the maintenance of proper higher-order
CC       structure of DNA during mitosis. Involved in chromosome condensation
CC       and proper cytokinesis. Nucleosomes are preferred as substrate compared
CC       to free histones. Mediates monomethylation of p53/TP53 at 'Lys-382',
CC       leading to repress p53/TP53-target genes. Plays a negative role in TGF-
CC       beta response regulation and a positive role in cell migration.
CC       {ECO:0000269|PubMed:12086618, ECO:0000269|PubMed:12121615,
CC       ECO:0000269|PubMed:15200950, ECO:0000269|PubMed:15933069,
CC       ECO:0000269|PubMed:15933070, ECO:0000269|PubMed:16517599,
CC       ECO:0000269|PubMed:17707234, ECO:0000269|PubMed:23478445}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=L-lysyl(20)-[histone H4] + S-adenosyl-L-methionine = H(+) +
CC         N(6)-methyl-L-lysyl(20)-[histone H4] + S-adenosyl-L-homocysteine;
CC         Xref=Rhea:RHEA:60344, Rhea:RHEA-COMP:15554, Rhea:RHEA-COMP:15555,
CC         ChEBI:CHEBI:15378, ChEBI:CHEBI:29969, ChEBI:CHEBI:57856,
CC         ChEBI:CHEBI:59789, ChEBI:CHEBI:61929; EC=2.1.1.361;
CC         Evidence={ECO:0000255|PROSITE-ProRule:PRU00904,
CC         ECO:0000269|PubMed:12086618, ECO:0000269|PubMed:12121615,
CC         ECO:0000269|PubMed:15964846};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=L-lysyl-[protein] + S-adenosyl-L-methionine = H(+) + N(6)-
CC         methyl-L-lysyl-[protein] + S-adenosyl-L-homocysteine;
CC         Xref=Rhea:RHEA:51736, Rhea:RHEA-COMP:9752, Rhea:RHEA-COMP:13053,
CC         ChEBI:CHEBI:15378, ChEBI:CHEBI:29969, ChEBI:CHEBI:57856,
CC         ChEBI:CHEBI:59789, ChEBI:CHEBI:61929; Evidence={ECO:0000305};
CC   -!- SUBUNIT: Interacts with L3MBTL1. Isoform 2 interacts with SIRT2
CC       (phosphorylated form); the interaction is direct, stimulates KMT5A-
CC       mediated methyltransferase activity at histone H4 'Lys-20' (H4K20me1)
CC       and is increased in a H(2)O(2)-induced oxidative stress-dependent
CC       manner. {ECO:0000269|PubMed:15933069, ECO:0000269|PubMed:15933070,
CC       ECO:0000269|PubMed:18408754, ECO:0000269|PubMed:23468428}.
CC   -!- INTERACTION:
CC       Q9NQR1; P62805: H4C9; NbExp=6; IntAct=EBI-1268946, EBI-302023;
CC       Q9NQR1; P07910: HNRNPC; NbExp=2; IntAct=EBI-1268946, EBI-357966;
CC       Q9NQR1; Q15672: TWIST1; NbExp=5; IntAct=EBI-1268946, EBI-1797287;
CC   -!- SUBCELLULAR LOCATION: Nucleus. Chromosome. Note=Specifically localizes
CC       to mitotic chromosomes. Colocalized with SIRT2 at mitotic foci.
CC       Associates with chromosomes during mitosis; association is increased in
CC       a H(2)O(2)-induced oxidative stress-dependent manner. Associates with
CC       silent chromatin on euchromatic arms. Not associated with constitutive
CC       heterochromatin.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q9NQR1-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q9NQR1-2; Sequence=VSP_002226, VSP_002227;
CC   -!- DEVELOPMENTAL STAGE: Not detected during G1 phase. First detected
CC       during S through G2 phases, and peaks during mitosis (at protein
CC       level). {ECO:0000269|PubMed:12208845}.
CC   -!- INDUCTION: By HCFC1 C-terminal chain, independently of HCFC1 N-terminal
CC       chain. Transiently induced by TGF-beta and during the cell cycle.
CC       {ECO:0000269|PubMed:15200950, ECO:0000269|PubMed:23478445}.
CC   -!- DOMAIN: Although the SET domain contains the active site of enzymatic
CC       activity, both sequences upstream and downstream of the SET domain are
CC       required for methyltransferase activity.
CC   -!- PTM: Acetylated at Lys-172; does not change methyltransferase activity.
CC       Deacetylated at Lys-172 by SIRT2; does not change methyltransferase
CC       activity. {ECO:0000269|PubMed:23468428}.
CC   -!- PTM: Ubiquitinated and degraded by the DCX(DTL) complex.
CC       {ECO:0000305|PubMed:23478445}.
CC   -!- SIMILARITY: Belongs to the class V-like SAM-binding methyltransferase
CC       superfamily. Histone-lysine methyltransferase family. PR/SET subfamily.
CC       {ECO:0000255|PROSITE-ProRule:PRU00904}.
CC   -!- CAUTION: It is uncertain whether Met-1 or Met-72 is the initiator.
CC       {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAL40879.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AY064546; AAL40879.1; ALT_INIT; mRNA.
DR   EMBL; AY102937; AAM47033.1; -; mRNA.
DR   EMBL; AF287261; AAF97812.2; -; mRNA.
DR   EMBL; AK292645; BAF85334.1; -; mRNA.
DR   EMBL; BC050346; AAH50346.1; -; mRNA.
DR   CCDS; CCDS9247.1; -. [Q9NQR1-2]
DR   RefSeq; NP_001311433.1; NM_001324504.1.
DR   RefSeq; NP_001311434.1; NM_001324505.1.
DR   RefSeq; NP_001311435.1; NM_001324506.1.
DR   RefSeq; NP_065115.3; NM_020382.4. [Q9NQR1-2]
DR   PDB; 1ZKK; X-ray; 1.45 A; A/B/C/D=231-393.
DR   PDB; 2BQZ; X-ray; 1.50 A; A/E=233-393.
DR   PDB; 3F9W; X-ray; 1.60 A; A/B/C/D=232-393.
DR   PDB; 3F9X; X-ray; 1.25 A; A/B/C/D=232-393.
DR   PDB; 3F9Y; X-ray; 1.50 A; A/B=232-393.
DR   PDB; 3F9Z; X-ray; 1.60 A; A/B/C/D=232-393.
DR   PDB; 4IJ8; X-ray; 2.00 A; A/B=232-393.
DR   PDB; 5HQ2; X-ray; 4.50 A; M=194-393.
DR   PDB; 5T5G; X-ray; 2.10 A; A=234-380.
DR   PDB; 5TEG; X-ray; 1.30 A; A/B=234-393.
DR   PDB; 5TH7; X-ray; 1.95 A; A/B=234-380.
DR   PDB; 5V2N; X-ray; 2.00 A; A=231-393.
DR   PDB; 5W1Y; X-ray; 1.70 A; A/B=232-393.
DR   PDB; 6BOZ; X-ray; 2.40 A; A/B=232-393.
DR   PDBsum; 1ZKK; -.
DR   PDBsum; 2BQZ; -.
DR   PDBsum; 3F9W; -.
DR   PDBsum; 3F9X; -.
DR   PDBsum; 3F9Y; -.
DR   PDBsum; 3F9Z; -.
DR   PDBsum; 4IJ8; -.
DR   PDBsum; 5HQ2; -.
DR   PDBsum; 5T5G; -.
DR   PDBsum; 5TEG; -.
DR   PDBsum; 5TH7; -.
DR   PDBsum; 5V2N; -.
DR   PDBsum; 5W1Y; -.
DR   PDBsum; 6BOZ; -.
DR   SMR; Q9NQR1; -.
DR   BioGRID; 132490; 36.
DR   DIP; DIP-39133N; -.
DR   IntAct; Q9NQR1; 39.
DR   MINT; Q9NQR1; -.
DR   STRING; 9606.ENSP00000384629; -.
DR   BindingDB; Q9NQR1; -.
DR   ChEMBL; CHEMBL1795176; -.
DR   GuidetoPHARMACOLOGY; 2704; -.
DR   iPTMnet; Q9NQR1; -.
DR   PhosphoSitePlus; Q9NQR1; -.
DR   BioMuta; KMT5A; -.
DR   DMDM; 25091219; -.
DR   jPOST; Q9NQR1; -.
DR   MassIVE; Q9NQR1; -.
DR   MaxQB; Q9NQR1; -.
DR   PaxDb; Q9NQR1; -.
DR   PeptideAtlas; Q9NQR1; -.
DR   PRIDE; Q9NQR1; -.
DR   ProteomicsDB; 82171; -. [Q9NQR1-1]
DR   ProteomicsDB; 82172; -. [Q9NQR1-2]
DR   Antibodypedia; 31806; 593 antibodies.
DR   DNASU; 387893; -.
DR   Ensembl; ENST00000402868; ENSP00000384629; ENSG00000183955. [Q9NQR1-2]
DR   GeneID; 387893; -.
DR   KEGG; hsa:387893; -.
DR   UCSC; uc001uew.4; human. [Q9NQR1-1]
DR   CTD; 387893; -.
DR   DisGeNET; 387893; -.
DR   GeneCards; KMT5A; -.
DR   HGNC; HGNC:29489; KMT5A.
DR   HPA; ENSG00000183955; Low tissue specificity.
DR   MIM; 607240; gene.
DR   neXtProt; NX_Q9NQR1; -.
DR   OpenTargets; ENSG00000183955; -.
DR   PharmGKB; PA143485616; -.
DR   VEuPathDB; HostDB:ENSG00000183955.12; -.
DR   eggNOG; KOG1085; Eukaryota.
DR   GeneTree; ENSGT00940000160030; -.
DR   InParanoid; Q9NQR1; -.
DR   OMA; KWCIDAT; -.
DR   OrthoDB; 1460495at2759; -.
DR   PhylomeDB; Q9NQR1; -.
DR   TreeFam; TF335181; -.
DR   BioCyc; MetaCyc:HS11381-MONOMER; -.
DR   BRENDA; 2.1.1.43; 2681.
DR   PathwayCommons; Q9NQR1; -.
DR   Reactome; R-HSA-2299718; Condensation of Prophase Chromosomes.
DR   Reactome; R-HSA-3214841; PKMTs methylate histone lysines.
DR   Reactome; R-HSA-6804760; Regulation of TP53 Activity through Methylation.
DR   SABIO-RK; Q9NQR1; -.
DR   SIGNOR; Q9NQR1; -.
DR   BioGRID-ORCS; 387893; 72 hits in 981 CRISPR screens.
DR   ChiTaRS; KMT5A; human.
DR   EvolutionaryTrace; Q9NQR1; -.
DR   GeneWiki; SETD8; -.
DR   GenomeRNAi; 387893; -.
DR   Pharos; Q9NQR1; Tchem.
DR   PRO; PR:Q9NQR1; -.
DR   Proteomes; UP000005640; Chromosome 12.
DR   RNAct; Q9NQR1; protein.
DR   Bgee; ENSG00000183955; Expressed in sural nerve and 165 other tissues.
DR   ExpressionAtlas; Q9NQR1; baseline and differential.
DR   Genevisible; Q9NQR1; HS.
DR   GO; GO:0005694; C:chromosome; IEA:UniProtKB-SubCell.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0018024; F:histone-lysine N-methyltransferase activity; IDA:UniProtKB.
DR   GO; GO:0002039; F:p53 binding; IPI:UniProtKB.
DR   GO; GO:0016279; F:protein-lysine N-methyltransferase activity; IDA:UniProtKB.
DR   GO; GO:0003714; F:transcription corepressor activity; IDA:UniProtKB.
DR   GO; GO:0051301; P:cell division; IEA:UniProtKB-KW.
DR   GO; GO:0034770; P:histone H4-K20 methylation; IEA:GOC.
DR   GO; GO:0007076; P:mitotic chromosome condensation; TAS:Reactome.
DR   GO; GO:0000122; P:negative regulation of transcription by RNA polymerase II; IMP:UniProtKB.
DR   GO; GO:0045892; P:negative regulation of transcription, DNA-templated; IDA:UniProtKB.
DR   GO; GO:0018026; P:peptidyl-lysine monomethylation; IDA:UniProtKB.
DR   GO; GO:0043516; P:regulation of DNA damage response, signal transduction by p53 class mediator; IMP:UniProtKB.
DR   GO; GO:1901796; P:regulation of signal transduction by p53 class mediator; TAS:Reactome.
DR   IDEAL; IID00101; -.
DR   InterPro; IPR016858; Hist_H4-K20_MeTrfase.
DR   InterPro; IPR001214; SET_dom.
DR   Pfam; PF00856; SET; 1.
DR   SMART; SM00317; SET; 1.
DR   PROSITE; PS51571; SAM_MT43_PR_SET; 1.
DR   PROSITE; PS50280; SET; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative splicing; Cell cycle; Cell division;
KW   Chromatin regulator; Chromosome; Coiled coil; Direct protein sequencing;
KW   Methyltransferase; Mitosis; Nucleus; Phosphoprotein; Reference proteome;
KW   Repressor; S-adenosyl-L-methionine; Transcription;
KW   Transcription regulation; Transferase; Ubl conjugation.
FT   CHAIN           1..393
FT                   /note="N-lysine methyltransferase KMT5A"
FT                   /id="PRO_0000186081"
FT   DOMAIN          257..378
FT                   /note="SET"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00190"
FT   REGION          267..269
FT                   /note="S-adenosyl-L-methionine binding"
FT   REGION          339..340
FT                   /note="S-adenosyl-L-methionine binding"
FT   COILED          134..163
FT                   /evidence="ECO:0000255"
FT   COMPBIAS        6..67
FT                   /note="Ala-rich"
FT   COMPBIAS        29..32
FT                   /note="Poly-Arg"
FT   BINDING         312
FT                   /note="S-adenosyl-L-methionine"
FT   MOD_RES         100
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:20068231"
FT   MOD_RES         172
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000269|PubMed:23468428"
FT   MOD_RES         181
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   VAR_SEQ         1..41
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:12121615,
FT                   ECO:0000303|PubMed:14702039, ECO:0000303|PubMed:15489334"
FT                   /id="VSP_002226"
FT   VAR_SEQ         42..57
FT                   /note="PGRAAGGKMSKPCAVE -> MARGRKMSKPRAVEAA (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:12121615,
FT                   ECO:0000303|PubMed:14702039, ECO:0000303|PubMed:15489334"
FT                   /id="VSP_002227"
FT   MUTAGEN         172
FT                   /note="K->Q: Inhibits the interaction with SIRT2. Increases
FT                   the number of mitotic foci formation. Does not change
FT                   methyltransferase activity."
FT                   /evidence="ECO:0000269|PubMed:23468428"
FT   MUTAGEN         172
FT                   /note="K->R: Increases the interaction with SIRT2. Reduces
FT                   the number of mitotic foci formation. Does not change
FT                   methyltransferase activity."
FT                   /evidence="ECO:0000269|PubMed:23468428"
FT   MUTAGEN         286
FT                   /note="Y->A,F: Strongly reduces affinity for histone H4 and
FT                   abolishes methyltransferase activity."
FT                   /evidence="ECO:0000269|PubMed:15933070"
FT   MUTAGEN         300
FT                   /note="E->A: Strongly reduces affinity for histone H4."
FT                   /evidence="ECO:0000269|PubMed:15933070"
FT   MUTAGEN         311
FT                   /note="C->A: Strongly reduces affinity for histone H4."
FT                   /evidence="ECO:0000269|PubMed:15933070"
FT   MUTAGEN         336
FT                   /note="R->G: Abolishes methyltransferase activity."
FT                   /evidence="ECO:0000269|PubMed:12086618,
FT                   ECO:0000269|PubMed:23478445"
FT   MUTAGEN         340
FT                   /note="H->A: Strongly decreases methyltransferase
FT                   activity."
FT                   /evidence="ECO:0000269|PubMed:12121615"
FT   MUTAGEN         375
FT                   /note="Y->A: Strongly reduces affinity for histone H4 and
FT                   methyltransferase activity."
FT                   /evidence="ECO:0000269|PubMed:15933070"
FT   MUTAGEN         375
FT                   /note="Y->F: Alters methyltransferase activity, so that
FT                   both monomethylation and dimethylation take place."
FT                   /evidence="ECO:0000269|PubMed:15933070"
FT   MUTAGEN         379
FT                   /note="D->A,N: Abolishes histone H4 binding and
FT                   methyltransferase activity."
FT                   /evidence="ECO:0000269|PubMed:15933070,
FT                   ECO:0000269|PubMed:17707234, ECO:0000269|PubMed:20870725,
FT                   ECO:0000269|PubMed:23478445"
FT   MUTAGEN         385..393
FT                   /note="Missing: Abolishes methyltransferase activity."
FT                   /evidence="ECO:0000269|PubMed:12121615"
FT   MUTAGEN         388
FT                   /note="H->A,E: Strongly reduces affinity for histone H4."
FT                   /evidence="ECO:0000269|PubMed:15933070"
FT   MUTAGEN         388
FT                   /note="H->F: Increases affinity for histone H4."
FT                   /evidence="ECO:0000269|PubMed:15933070"
FT   CONFLICT        162..163
FT                   /note="KG -> RR (in Ref. 3; AAF97812)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        281
FT                   /note="D -> A (in Ref. 3; AAF97812)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        343
FT                   /note="C -> R (in Ref. 3; AAF97812)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        357
FT                   /note="P -> R (in Ref. 5; AAH50346)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        373
FT                   /note="L -> P (in Ref. 3; AAF97812)"
FT                   /evidence="ECO:0000305"
FT   HELIX           236..253
FT                   /evidence="ECO:0007744|PDB:3F9X"
FT   STRAND          259..264
FT                   /evidence="ECO:0007744|PDB:3F9X"
FT   TURN            265..267
FT                   /evidence="ECO:0007744|PDB:3F9X"
FT   STRAND          268..275
FT                   /evidence="ECO:0007744|PDB:3F9X"
FT   STRAND          282..285
FT                   /evidence="ECO:0007744|PDB:3F9X"
FT   STRAND          288..292
FT                   /evidence="ECO:0007744|PDB:3F9X"
FT   HELIX           293..303
FT                   /evidence="ECO:0007744|PDB:3F9X"
FT   HELIX           307..309
FT                   /evidence="ECO:0007744|PDB:5TH7"
FT   HELIX           310..312
FT                   /evidence="ECO:0007744|PDB:4IJ8"
FT   STRAND          313..318
FT                   /evidence="ECO:0007744|PDB:3F9X"
FT   STRAND          321..326
FT                   /evidence="ECO:0007744|PDB:3F9X"
FT   HELIX           335..337
FT                   /evidence="ECO:0007744|PDB:3F9X"
FT   STRAND          338..340
FT                   /evidence="ECO:0007744|PDB:5TH7"
FT   STRAND          345..353
FT                   /evidence="ECO:0007744|PDB:3F9X"
FT   STRAND          356..365
FT                   /evidence="ECO:0007744|PDB:3F9X"
FT   STRAND          372..375
FT                   /evidence="ECO:0007744|PDB:5TH7"
FT   TURN            377..380
FT                   /evidence="ECO:0007744|PDB:5V2N"
FT   HELIX           382..387
FT                   /evidence="ECO:0007744|PDB:3F9X"
FT   HELIX           389..392
FT                   /evidence="ECO:0007744|PDB:3F9X"
SQ   SEQUENCE   393 AA;  42890 MW;  2DCD9B697834B5BD CRC64;
     MGEGGAAAAL VAAAAAAAAA AAAVVAGQRR RRLGRRARCH GPGRAAGGKM SKPCAVEAAA
     AAVAATAPGP EMVERRGPGR PRTDGENVFT GQSKIYSYMS PNKCSGMRFP LQEENSVTHH
     EVKCQGKPLA GIYRKREEKR NAGNAVRSAM KSEEQKIKDA RKGPLVPFPN QKSEAAEPPK
     TPPSSCDSTN AAIAKQALKK PIKGKQAPRK KAQGKTQQNR KLTDFYPVRR SSRKSKAELQ
     SEERKRIDEL IESGKEEGMK IDLIDGKGRG VIATKQFSRG DFVVEYHGDL IEITDAKKRE
     ALYAQDPSTG CYMYYFQYLS KTYCVDATRE TNRLGRLINH SKCGNCQTKL HDIDGVPHLI
     LIASRDIAAG EELLYDYGDR SKASIEAHPW LKH
//
